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The title of this review raises a simple question 
which, some years ago, when our knowledge about 
inhalation therapy was not so advanced, would prob- 
ably have been answered in a fairly straightforward 
manner. However, recent findings have made the 
issue of inhalation therapy much more complex. The 
ideal inhaler does not exist, so it is not possible to 
give a simple answer to a simple question. Instead, 
general features and the advantages and disadvan- 
tages of each individual inhalation system have to be 
considered. 
At present, four different groups of inhalation 
systems constitute the cornerstone in inhalation 
therapy in asthma: 
(1) conventional metered dose inhalers (MDI); 
(2) MD1 with a spacer attached; 
(3) dry powder inhalers (DPI); and 
(4) nebulizers. 
Within and between each group there are marked 
differences with respect to design, construction, aero- 
sol cloud generation, output characteristics, depo- 
sition pattern of the inhaled particles, optimal 
inhalation technique and ease of use. In addition to 
these variables, there are other factors to consider 
when prescribing an inhaler: 
(1) Conclusions from studies with one drug 
delivered from one inhaler may differ from the conclu- 
sions from another drug from the same inhaler; i.e. 
terbutaline delivered from a MD1 with an Aero- 
chamber results in about 7% deposition within the 
intrapulmonary airways whereas salbutamol MD1 or 
fenoterol MD1 with an Aerochamber produce 12% 
and 21% intrapulmonary deposition, respectively (1). 
Similarly, a nebulizer may produce a high deposition 
of salbutamol in the intrapulmonary airways whereas 
little or no drug delivery to this region is achieved 
when the same nebulizer is used with beclomethasone. 
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(2) Conclusions from adult studies may not be 
transferable to children. The nominal dose of budeso- 
nide particles <5,~rn reaching a cascade impactor 
through a model of an anatomical adult throat is 
around 20% from a MD1 and 40% from a MD1 with a 
Nebuhaler. The corresponding figures are 8% (MDI) 
and 27% (Nebuhaler) through a model of an ana- 
tomical child throat. Similar, often unpredictable 
differences between adults and children have been 
reported with other inhalers and drugs. 
(3) Some, but not all, of the new CFC-free MDIs 
have completely different in vitro output characteris- 
tics as compared with the present CFC containing 
inhalers. This means that in the future we may see 
marked differences in effects between two MDIs 
delivering the same drug so that equi-effective doses of 
the same drug may be 25 pg and 100 pug from two 
different MDIs. This will further complicate simple 
prescription and comparisons of inhalers. 
(4) Within the childhood population, drug delivery 
to the patient varies with the age of the child (2) and 
many inhalers cannot be used at all by young children 
or older people. 
Thus each inhaler should ideally be characterized 
for difference age groups with each drug used in the 
inhaler. This has not been done. Therefore, inhaler 
choice has to be based upon some more general, 
superior considerations. 
The most important questions to consider when 
prescribing an inhaler are: 
(1) Which inhaler is the most simple and easiest to 
use optimally for various age groups of 
patients? 
(2) Which inhaler most reproducibly delivers 
the highest fraction of the delivered dose to 
the intrapulmonary airways in different age 
groups using the inhaler optimally? As men- 
tioned earlier, this may vary from one drug to 
another. 
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Fig. I Pharmacokinetics of inhaled drugs. The majority of drug deposited in the lungs is systemically absorbed. Drug 
deposited in the mouth and oropharynx is swallowed and subsequently absorbed from the gut with subsequent inactivation 
in the liver. The various drugs differ in percentage that is inactivated by first pass metabolism in the liver and hence systemic 
bioavailability. 
(3) Which inhaler has the best clinical effect for a 
given systemic effect (therapeutic ratio) in the 
day-to-day treatment? 
(4) Which inhaler is preferred by the patient? 
Over the years, many investigators have reported 
high frequencies of improper inhaler use as a direct 
and major cause of treatment failure (3). Therefore, 
accurate knowledge among physicians about the 
nature and magnitude of the problems patients 
experience with inhalation therapy, and about which 
age groups can normally use the various inhalation 
devices correctly is important for correct inhaler 
prescription. For the average patient, a simple 
inhalation technique, easy handling, and a smart, 
convenient design are probably more important than 
a 25% higher drug delivery to the intrapulmonary 
airways. 
Therapeutic Ratio 
The therapeutic ratio is the ratio between the 
clinical effect and the systemic effect of an inhalation 
(clinical effect/systemic effect ratio). The systemic 
effect of a corticosteriod depends upon the amount of 
drug deposited in and systemically absorbed from the 
intrapulmonary airways, and the amount absorbed 
from the gastrointestinal tract (Fig. 1). The clinical 
effect only depends upon the deposition in the 
intrapulmonary airways. Therefore, a clinically effec- 
tive inhaler with high intrapulmonary drug deposi- 
tion will also be expected to have a higher systemic 
effect than an inhaler which is less effective clinically. 
In contrast, the contribution of the orally deposited 
drug to the systemic effect is higher for an inhaler 
with a low intrapulmonary and high oral drug depo- 
sition. When an inhaler is studied it is important to 
evaluate both the effect and side-effect profile so that 
an effect/side-effect ratio can be defined. If this is not 
done, false conclusions may be drawn from inhaler or 
drug comparisons; i.e. if 1OOOpg corticosteroid from 
Inhaler A reduces urinary cortisol excretion by 20% 
and 1000 pg from Inhaler B reduces it by 40% it may 
be concluded that Inhaler A is preferable to Inhaler 
B. If, however, Inhaler B is twice as clinically effective 
as A, then there is no difference between the two 
inhalers since the dose in Inhaler B can be reduced by 
50% and still be as effective as A. So, for the same 
clinical effect, the two inhalers have similar systemic 
effects. Similar results on cortisol excretion could also 
be seen after inhalation of a corticosteroid with a low 
first pass metabolism from an ineffective inhaler with 
high oropharyngeal deposition, and a corticosteroid 
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Fig. 2 Systemic availability (and hence systemic activity) 
of corticosteroid delivered from three different inhalers (A, 
B and C). All inhalers deliver 90% of the nominal dose to 
the patient. Inhaler A delivers 10% of the nominal dose to 
the intrapuhnonary airways and 80% to the oropharynx. 
Inhaler B delivers 20% to the intrapuhnonary airways and 
70% to the oropharynx. Inhaler C delivers 30% to the 
intrapulmonary airways and 60% to the oropharynx. The 
amount of systemically bioavailable drug depends upon 
lung deposition and upon the amount absorbed from the 
gastrointestinal tract; the latter being inversely related to the 
first pass metabolism of the drug. If 4OOpg corticosteroid 
from Inhaler B reduces urinary cortisol excretion by 40% 
and 400~11 from Inhaler A only reduces it by 20%, it may be 
concluded that Inhaler A is preferable to Inhaler B. If, 
however, Inhaler B is twice as effective as A clinically (as is 
the case in the figure), then there is no difference between 
the two inhalers since the dose in Inhaler B can be reduced 
by 50% and still be as effective as A. So, for the same clinical 
effect the two inhalers have similar systemic effects. In fact 
Inhaler B may even be preferable to A if the steroid used has 
a low first pass metabolism! Similar results on cortisol 
excretion could also be seen if the corticosteroid used had a 
high systemic bioavailability of drug deposited in the 
oropharynx, and Inhaler C was three times more effective 
than Inhaler A but delivered at a substantially lower dose to 
the oropharynx than Inhaler A. 
with a high first pass metabolism inhaled from a very 
effective inhaler delivering three times as much drug 
to the intrapulmonary airways (Fig. 2)! 
Most studies evaluating the use of inhaled corticos- 
teroids have only compared the systemic effect of the 
same dose of a corticosteroid delivered from two 
different inhalers, without considering the question of 
clinically equi-effective doses of the two inhalers 
studied. In such studies, it has been shown that 
beclomethasone delivered via a spacer (Volumatic) 
has less systemic activity than the same dose de- 
livered from a MD1 or a Diskhaler (4-6). Since the 
Volumatic seems to be at least as effective as these 
inhalers, the clinical effect/systemic effect ratio for the 
Volumatic is probably better than the ratio for these 
inhalers. Furthermore, budesonide from a Nebuhaler 
has the same systemic effect as budesonide from a 
MDI, and less systemic effect than budesonide from a 
Turbuhaler (74). However, the Turbuhaler is more 
effective than these inhalers. So, the higher systemic 
effect of the Turbuhaler is mainly due to a higher 
Fig. 3 Approximate therapeutic ratio of different 
corticosteroid-inhaler combinations. L, drug becoming 
systemically bioavailable by absorption from the lung 
(intrapulmonary airways); T, total amount of systemically 
bioavailable drug (the sum of absorption from the lungs and 
from the oropharynx and gastrointestinal tract). The ratios 
have been calculated upon data available in the literature. 
No published data exist for beclomethasone dipropionate. 
The therapeutic ratio expresses how much of the systemic 
bioavailability of an inhaled drug is derived from absorp- 
tion of drug from the lung. A ratio of 1 is ideal since it 
means that all systemically available drug comes from drug 
deposited in the intrapulmonary airways. MDI, metered 
dose inhaler; Turbu, Turbuhaler; Disk, Diskhaler. 
intrabronchial deposition, and hence the therapeutic 
ratio is almost the same for this inhaler and the 
Nebuhaler (Fig. 3). 
At present, there is no knowledge about the clinical 
therapeutic ratio for the various nebulizer systems, 
although a recent study suggested that important 
differences may exist (9). Nose breathing, which is 
common in young children, would be expected to 
filter off the large particles, which for some drugs are 
likely to be absorbed and cause systemic effects 
without adding to the clinical effect. Jet nebulizers 
with spacer-like reservoirs, which filter off the large 
particles, are likely to improve the therapeutic ratio. 
In summary, if the therapeutic ratio was the only 
determining factor for inhaler choice, spacer systems 
should be preferred to other inhalers for delivering 
inhaled steroids, which have a high systemic bioavail- 
ability of drug deposited in the oropharynx. How- 
ever, recent findings with the dry powder inhaler, 
Turbuhaler, show that the therapeutic ratio of this 
inhaler is quite similar to that of a spacer. Further- 
more, the low oral bioavailability of fluticasone 
dipropionate also means that this drug has almost the 
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same therapeutic ratio (which is close to 1) indepen- 
dent of delivery system. The difference in therapeutic 
ratio between the various inhalers is clinically of 
most importance when high doses of inhaled 
corticosteroids are used. 
Modes of Inhaler Assessment 
When information about an inhaler is assessed, it 
is important to consider how the information was 
derived since inhalers can be evaluated in many 
different ways (lo), including in vitro measurements, 
radioactive deposition studies, pharmacokinetic 
studies, filter studies, and clinical effect studies, which 
may be divided into laboratory studies, and clinical 
trials of the day-to-day treatment of patients. 
The various methods are complementary since they 
provide somewhat different information. At present, 
the clinical implications of the small-but 
statistically significant - differences obtained under 
standardized laboratory conditions which may be 
rather different from the daily treatment of out- 
patients when simplicity and ease of use may be more 
important. 
In the following, some important aspects of 
the four most widely used inhaler systems will be 
discussed. 
Pressurized Metered Dose Inhalers 
EASE OF USE 
MDIs are convenient, portable inhalers which are 
very difficult to use correctly, mainly because of the 
high velocity of the aerosol particles (100 km h- ‘) 
when leaving the mouthpiece: problems with correct 
coordination of actuation and inhalation, stopping 
inhalation when the cold aerosol particles reach the 
soft palate (cold freon effect), actuation of the aerosol 
into the mouth followed by inhalation through the 
nose, and a rapid inhalation (3,11-13). All these 
problems are associated with a reduced clinical effect. 
As a consequence, more than 50% of patients receiv- 
ing inhalation therapy with a MD1 can be expected to 
gain reduced or no clinical benefit from the pre- 
scribed medication (11) as compared with spacers or 
dry powder inhalers. Therefore, all prescriptions of a 
MD1 should be accompanied by repeated, thorough 
tuition of correct inhaler use followed by the patient’s 
demonstration of inhalation technique. Conventional 
MDIs are not normally the best choice for children 
or elderly patients if alternative devices are available. 
Use of a breath-actuated MD1 (Autohaler) will 
reduce tuition time, abolish coordination difficulties 
(14) and hence improve the dose to the intra- 
pulmonary airways in patients with this problem 
(15). The cold freon effect and the problem of nasal 
inhalation are unaffected, however, and this inhaler 
should mainly be reserved for patients older than 67 
years since they can be taught a correct inhalation 
technique with the Autohaler within 2-3 min, and 
also use it during episodes of acute wheeze (16,17). 
INHALATION TECHNIQUE 
Generally about 80% of the dose from a conven- 
tional PA lodges in the oropharynx, 10% is retained 
in the inhaler and 10% is deposited in the intra- 
pulmonary airways (3,18-20). There may be some 
differences between the various MD1 brands. The 
mode of inhalation influences the pulmonary deposi- 
tion. Very slow inhalations (N 30 1 min - i) followed 
by a breath-holding pause of 10 s after the inhalation 
have been found to enhance pulmonary deposition as 
compared with fast inhalations (about 90 1 min - i) 
with and without a breath-holding pause (3, 19-23). 
Actuating the aerosol 4 cm from the wide-open 
mouth has been suggested to increase pulmonary 
deposition when compared to actuations with the lips 
closed around the mouthpiece of the inhaler. How- 
ever, the results from studies evaluating this have 
been inconsistent (3). Consequently, it is very diffi- 
cult to teach most patients an optimal inhalation 
technique. 
Spacers 
Various holding chambers (spacers) may be 
attached to the mouthpiece of a conventional pres- 
surized aerosol. These devices ensure that the aerosol 
particles have a slower velocity and a smaller particle 
size when they reach the patient which is a theoretical 
advantage. Many spacers have a one-way valve that 
opens during inspiration and closes during expira- 
tion. This makes them easier to use than a MDI. A 
substantial amount of drug may be lost through the 
valve when the aerosol is fired into a straight tube 
spacer if the valve is not tight. 
EASE OF USE 
All spacers reduce the risk of the cold freon effect 
and the occurrence of coordination problems. There- 
fore, spacers are easier to use than a MD1 (3) and 
some produce a better clinical effect, particularly if 
they have a valve system. Virtually all adults and 
school children can learn how to use these devices 
and also use them effectively during attacks of acute 
bronchoconstriction when they are as effective as 
nebulizers (24,25). Furthermore, at present, spacers 
are probably the inhaler of choice in preschool 
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children (2632). During episodes of acute wheeze, 
however, many young children may not be able to 
open or close the valve system of some spacers like 
Nebuhaler and Volumatic and therefore not gain 
optimal benefit. The main problem with spacers is 
that they are bulky and difficult to carry about. They 
are more suitable for prophylactic treatment given at 
home, morning and evening. 
INHALATION TECHNIQUE 
Slow inhalations (around 30 1 min - ‘) improve the 
effect when a straight extension tube spacer is used in 
children, whereas breath-holding, tilting of the head 
during inhalation, or inhalation from functional 
residual capacity instead of residual volume does not 
influence the effect (3,33). This is in good agreement 
with the finding that slow, quiet tidal breathing 
results in an optimal effect when a Nebuhaler is used 
(34). In contrast, slow inhalations may not be of 
similar importance in adults. So, optimal inhalation 
from a spacer is easier than from a MDJ. 
Only one dose should be fired into the spacer at a 
time. When two or more doses are used at a time, the 
inhaled dose is reduced (35-37). An advantage of 
large volume spacers is that the inhalation can be 
delayed for a few seconds after actuation without any 
significant reduction in effect (38). However, too long 
a delay decreases the number of inhaled particles 
~5 pm diameter (36). In contrast, the inhalation from 
a low volume spacer should not be delayed since that 
would result in an even greater loss of drug in the 
device. 
All spacers reduce the oropharyngeal deposition 
of drug substantially (19,21,39). As a result, the 
occurrence of oropharyngeal candida is reduced 
when corticosteroids are used. The amount of drug 
retained in the inhaler is increased markedly by all 
spacers (most by the low volume spacers) and 
hence the dose to the patient reduced. Yet the dose 
delivered to the intrapulmonary airways is often 
the same or higher than that from a MD1 
(18,19,21,39,40), though not all spacers have been 
thoroughly studied with respect to this. 
OTHER STUDIES 
The output of respirable particles from a spacer 
may be markedly improved by use of an antistatic 
lining in the spacer (36). Washing a spacer in soapy 
water will reduce the antistatic lining, which is 
normally produced by the daily actuations of drug 
into the spacer, and hence reduce drug output during 
the following days. Priming a new spacer or a newly 
washed spacer by firing some doses into it will 
improve output. It normally requires up to 15 doses 
to achieve optimal priming. The optimal frequency 
and mode of cleaning a spacer is not known. So 
maintenance of a spacer is more difficult than for a 
MDI. New metal spacers are now available in some 
countries. They totally eliminate the problems of 
static electricity. As a consequence, cleaning and 
washing do not influence output, and priming 
becomes redundant. 
The optimal volume of a spacer is not known. It is 
often anticipated that a low volume is advantageous 
in preschool children. However, some studies have 
indicated that the volume of the spacer is not so 
important in these age groups as is normally antici- 
pated. The reason for this seems to be that young 
children hyperventilate markedly when a tightly fit- 
ting face mask is placed around their mouth and nose 
(41). 
Due to their many advantages, a variety of new 
spacer systems are being launched every year. 
Though deceptively similar in appearance, there may 
be marked differences in the amount of drug retained 
in them and dose delivered to the intrapulmonary 
airways (42). Therefore, uncritical use of any new 
spacer is not recommended until its value has been 
documented in controlled trials. 
Dry Powder Inhalers 
In dry powder inhalers, the drug is provided as a 
finely milled powder in large aggregates (diameter of 
about 60pm), either alone or in combination with 
carrier particles. Most of the particles from dry 
powder inhalers are too large to penetrate into the 
lungs. However, the turbulent airstream created in 
the inhaler during inhalation causes the aggregates to 
break up into particles sufficiently small to be carried 
into the lower airways. Thus the effect of powder 
inhalers is dependent upon a certain minimum 
amount of energy from the patient’s inhalation to 
create the correct particle size of the drug. Up to a 
certain point, increases in flow rate will increase the 
number of particles within the ‘respirable range’ and 
the clinical effect of the inhalation (3,43). 
The most widely used dry powder inhalers are 
the Spinhaler, the Rotahaler, the Diskhaler and the 
Turbuhaler. These inhalers vary markedly in drug 
delivery characteristics. 
In the Spinhaler, the gelatine capsule is placed in 
the middle of a rotor. Even with an optimal inhala- 
tion technique, around 25% of the nominal dose is 
retained in the capsule and only 612% is deposited 
in the intrapulmonary airways (4346). 
The RotahaZer also uses gelatine capsules. After the 
capsule is broken, a coarse net causes turbulence 
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during the inhalation. Intrabronchial deposition with 
the Rotahaler varies from 611% in different studies 
when an optimal inhalation technique is used. 
Oropharyngeal deposition is around 80% (4649). 
In the Diskhaler, active drug and lactose are kept 
in an air-tight aluminium blister that is pierced before 
inhalation. The Diskhaler also uses a coarse net to 
disintegrate the particles. Intrabronchial deposition 
was found to be around 11% in two studies (50,51). 
In one, the deposition after Diskhaler was only half 
the intrabronchial deposition of a Volumatic (50). 
The Turbuhaler has a powder reservoir, which 
contains several doses of pure drug without any 
additives. During inhalation, the turbulence gener- 
ated in spiral-formed channels in the mouthpiece 
de-aggregates the large particles. Intrabronchial 
deposition with this inhaler varies from 17-32% in 
various studies (mean 25%). Between 20-25% is 
retained in the inhaler and around 50% is deposited 
in the oropharynx. The intrabronchial deposition 
after Turbuhaler has been found to be twice the 
deposition of a correctly used MD1 (20,49,52). 
CLINICAL STUDIES: EASE OF USE 
Even if an inhaler is somewhat more effective than 
other inhalers in the laboratory, it may not be 
advantageous in day-to-day treatment if it is more 
difficult to use. Dry powder inhalers are breath- 
actuated and therefore reduce/eliminate the co- 
ordination problems of actuation and inhalation, 
which are seen with the MD1 (3). For many years, 
DPIs have been single dose inhalers and therefore less 
convenient but easier to use than the MDI. Some 
children have difficulties with correct loading and 
splitting of the capsules when using the single dose 
inhalers, particularly during episodes of acute wheeze 
(3,53). In accordance with this, several recent studies 
have found that the new multiple DPIs are easier to 
use and more convenient, so these inhalers are pre- 
ferred to the single dose inhalers and MDIs in school 
children. 
The main problem with multi-dose DPIs is to train 
the patient not to exhale through the inhaler before 
the inhalation, since that will blow out the dose of the 
inhaler. Furthermore, Turbuhaler should be loaded 
in an upright position. Otherwise, the metered dose 
will be reduced when less than half the doses are left 
in the powder reservoir. 
INHALATION TECHNIQUE 
Fast inhalations enhance the effect of all DPIs in 
children, whereas breath-holding, tilting of the head 
during inhalation, or inhalation from functional 
residual capacity instead of residual volume does not 
influence the effect (3,43,54). So the inhalation tech- 
nique is simple. The number of respirable particles 
and the effect decrease with decreasing inspiratory 
flow rates. The inhalation effort and the inhalation 
flow rate needed to generate a therapeutic aerosol 
vary between different DPIs. Therefore, results 
obtained with one inhaler cannot be used to charac- 
terize another. At present, no correctly performed 
comparisons between the various DPIs have been 
done so the clinical importance of these differences is 
not known. They are most likely to be important in 
preschool children, who may not be able to generate 
such high inspiratory flow rates and therefore benefit 
less than older children from dry powder inhaler 
treatment (3,54). Until further studies are available, 
DPIs should preferably not be used in children 
younger than 5 years. 
Nebulizers 
In a jet nebulizer, air or oxygen from an electric 
compressor, hospital line or cylinder, passes through 
a narrow orifice, known as a venturi. Liquid from a 
reservoir is sucked up a tube and broken down into 
droplets. Only about 0.5% of this primary droplet 
mass (comprising the smallest droplets) leaves the 
nebulizer directly, the remaining 99.5% impacts on 
baffles within the nebulizer or on the internal walls 
(55). The liquid mass returns to the reservoir and 
is re-nebulized. Thus the nebulizer produces a con- 
tinuous spray over a treatment period of several 
minutes. 
During nebulization, a fall in temperature of the 
nebulizer and its contents is seen, typically 1&15”C, 
because the diluent evaporates during the nebuliza- 
tion. As a consequence, the drug concentration 
remaining in the nebulizer increases steadily during 
nebulization (56). It is not possible to deliver all the 
fluid as aerosol since some is trapped as a dead or 
residual volume within the nebulizer - even after 
nebulization to dryness, i.e. until no more spray is 
produced. Thus an initial volume fill of 4 ml might 
typically leave a dead volume of 1 ml, but it would be 
a mistake to think that three-quarters of the drug has 
been nebulized. If the drug concentration in the 
reservoir has doubled (as often occurs), then only 
50% of the drug has been nebulized. 
Drug output will vary according to the type of 
nebulizer, variation in dead volume, and the volume 
of fluid initially placed in the nebulizer. Nebulizers 
work more efficiently (deliver more drug) when 
higher volume fills are used. To give an example, it 
may be possible to release only 40% of the dose with 
a 2-ml fill, up to 60% with a 4-ml fill and even more 
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with a 6-ml fill (57). Furthermore, drug delivery can 
be markedly improved by using breath-actuated 
nebulizers, which deliver drug during inspiration 
alone. However, at present these devices are 
expensive and complicated. 
Information about droplet size provided by 
manufacturers of nebulizers is often sparse and some- 
times misleading. It is common practice for manufac- 
turers’ data to quote the number of particles smaller 
than a given size, for instance to say that 80% of the 
droplets are smaller than 5,um diameter. Since the 
mass of drug contained in any droplet is proportional 
to the cube of its radius, and a single 10pm droplet 
will contain that same amount of drug as 100 1 pm 
droplets, it is likely that most of the droplet mass will 
be contained in the 20% of droplets larger than 5 pm 
in diameter. It is therefore essential to quote droplet 
sizes from nebulizers in terms of mass or volume 
distribution if they are to have any meaning. Finally, 
the output characteristics of the nebulizer change 
during ageing. 
Ultrasonic nebulizers use a piezoelectric crystal 
vibrating at a high frequency to generate a fountain 
of liquid in the nebulizer chamber. They operate 
silently and normally produce droplets with a higher 
MMAD than jet nebulizers (55,58,59). Furthermore, 
they cannot be used for suspensions since they only 
nebulize the water and not the drug, they may not be 
able to make a spray from some viscous drug solu- 
tions, and they may cause damage to some drugs 
(58). For these reasons, ultrasonic nebulizers are not 
at present as widely used as jet nebulizers and they 
will not be discussed in detail. 
CLINICAL STUDIES: EASE OF USE 
Little coordination is required from the patient if 
continuous nebulization and a face mask with holes 
are used. Therefore, nebulizers are simple to use. 
However, compared with other devices, nebulizers 
are expensive, bulky, inconvenient, time consuming, 
inefficient delivery systems and, with our present 
knowledge, their use for daily treatment should be 
limited to patients who cannot be taught the correct 
use of another device or for drugs which cannot be 
delivered by any other inhaler system. In clinical 
practice, this means some children younger than 34 
years, mentally retarded patients and some elderly 
patients. 
In spite of all the problems with nebulized therapy, 
nebulizers are still the delivery system of choice in the 
treatment of acute severe asthma in all age groups, 
even if the same results can often be obtained with 
other inhalation systems (24,25,60,61). In the acute 
situation, it is advantageous that oxygen can be 
administered through the nebulizer at the same time 
as the &agonist. 
INHALATION TECHNIQUE 
No controlled studies have been done in children 
on the optimal inhalation technique. However, quiet 
tidal breathing is normally recommended because 
it produces optimal results in adults (62). So, the 
inhalation technique with nebulizers is simple. 
Inhalation through a face mask held 2-3 cm from 
the face reduces drug delivery by approximately 50%, 
with a corresponding increase in release of aerosol to 
the environment. In agreement with this, in vitro 
studies have reported an 85% reduction in the inhaled 
dose of respirable particles when the face mask was 
moved 2 cm from the inspiratory orifice (41). The 
effect appears to be the same whether the inhalation 
takes place through a mouth-piece or a face mask 
(60). 
OTHER STUDIES 
Simply varying the choice of compressor, jet 
nebulizer and volume fill has been shown to vary the 
mass of drug in respirable particles over a IO-fold 
range (63). Therefore, each nebulizerdrug combina- 
tion should ideally be characterized separately. This 
is never done. Due to this enormous variation, it is 
not meaningful to discuss comparisons with other 
inhalers in general. However, nebulizers are generally 
far less effective per mg drug than other inhaler 
systems. Thus, higher doses are required to achieve 
the same clinical effect (24,64). This difference in 
delivery seems to be more pronounced for steroids 
(65) than for &agonists because fewer respirable 
particles are generated from a steroid suspension. 
Summary of Inhaler Strategy 
It is obvious that many factors should be consid- 
ered when an inhaler is prescribed. Based upon the 
information discussed above, a rational inhaler 
strategy could be as follows: 
(1) Children I 5 years and elderly patients are 
prescribed a spacer with a valve system (and a 
face mask for the children) for the delivery of 
all drugs. When they are severely obstructed, 
some may need a nebulizer. If the patient 
cannot be taught the correct use of a spacer, a 
nebulizer should be prescribed. 
(2) Children 2 5 years and adults are prescribed a 
spacer or a Turbuhaler for the administration 
of inhaled corticosteroids and a dry powder 
inhaler (preferably multiple dose) or a 
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breath-actuated MD1 for other drugs. If these 
alternatives are not available or the patient 
prefers, a conventional MD1 can be used 
(preferably not for other corticosteroids than 
fluticasone propionate) provided that careful 
tuition is given. Fluticasone dipropionate may 
be given by DPI, Spacer or MDI. 
Nebulizers are mainly reserved for severe acute 
attacks of bronchoconstriction. 
With this approach, most patients can be taught 
effective inhaler use with a minimum of instructional 
time. Finally, it must always be remembered to 
consider the patient’s wish, since prescription of an 
inhaler which the physician likes but the patient does 
not is likely to reduce compliance. 
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